Grant C. Glatfelter*, Serena S. Schalk, Donna Walther, Alexander D. Maitland, Nicholas R. Gonzalez, John S. Partilla, Nicholas A. Anas, Andrew R. Chadeayne, Marilyn Naeem, David R. Manke, John D. McCorvy and Michael H. Baumann,
{"title":"Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy-N-methyl-N-isopropyltryptamine and Related Analogs","authors":"Grant C. Glatfelter*, Serena S. Schalk, Donna Walther, Alexander D. Maitland, Nicholas R. Gonzalez, John S. Partilla, Nicholas A. Anas, Andrew R. Chadeayne, Marilyn Naeem, David R. Manke, John D. McCorvy and Michael H. Baumann, ","doi":"10.1021/acschemneuro.6c00083","DOIUrl":null,"url":null,"abstract":"<p >Tryptamine psychedelics induce psychoactive effects via agonist actions at serotonin 2A receptors (5-HT<sub>2A</sub>), but the compounds are generally nonselective. 4-Methoxy-<i>N</i>-methyl-<i>N</i>-isopropyltryptamine (4-MeO-MiPT) is a 5-HT<sub>2A</sub> agonist which also blocks the 5-HT transporter (SERT) and has blunted visual and other psychedelic effects in humans. Here, we compared the pharmacology of 4-MeO-MiPT, its 4-hydroxy derivative (4-HO-MiPT), and related analogs with <i>N-</i>alkyl or 4-alkoxy variations. We hypothesized that compounds with more potent SERT uptake inhibition would display reduced 5-HT<sub>2A</sub>-mediated psychedelic-like effects in the mouse head twitch response (HTR) model. <i>In vitro</i> target profiling revealed potent and efficacious 5-HT receptor activities for most of the compounds, including 5-HT<sub>2A</sub> receptor agonism (EC<sub>50</sub> = 10–118 nM, <i>E</i><sub>max</sub> = 72–97% 5-HT). Importantly, 4-MeO-MiPT and its <i>N</i>,<i>N</i>-diisopropyl (4-MeO-DiPT) and <i>N</i>-methyl-<i>N</i>-cyclopropyl (4-MeO-McPT) analogs displayed more potent uptake inhibition at SERT (IC<sub>50</sub> = 17–107 nM) than their 4-OH counterparts (IC<sub>50</sub> = 280–423 nM). Studies administering the drugs subcutaneously to C57BL/6J mice revealed that 4-HO- and 4-MeO-MiPT (0.03–30 mg/kg) had similar potencies for inducing HTRs (ED<sub>50</sub> = 0.75 vs 0.97 mg/kg), but 4-MeO-MiPT had reduced efficacy (<i>E</i><sub>max</sub> = 77 vs 34 HTRs/30 min). A similar trend for decreased HTRs was observed for 4-MeO-DiPT and 4-MeO-McPT. Pretreatment with the SERT inhibitor fluoxetine (10 mg/kg) prior to 4-HO-MiPT, 4-HO-DiPT, or 4-HO-McPT reduced the maximal number of HTRs to levels observed for their respective 4-MeO analogs. Overall, our data indicate that 4-MeO-MiPT interacts with 5-HT<sub>2A</sub> and other 5-HT receptors, but the drug also inhibits SERT to reduce the efficacy of psychedelic-like effects in mice. Therefore, 4-MeO-MiPT and other dual 5-HT<sub>2A</sub>/SERT ligands may be therapeutically relevant compounds with reduced potential for traditional acute psychedelic effects.</p>","PeriodicalId":13,"journal":{"name":"ACS Chemical Neuroscience","volume":"17 12","pages":"2348–2363"},"PeriodicalIF":4.5000,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.6c00083","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Chemical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acschemneuro.6c00083","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Tryptamine psychedelics induce psychoactive effects via agonist actions at serotonin 2A receptors (5-HT2A), but the compounds are generally nonselective. 4-Methoxy-N-methyl-N-isopropyltryptamine (4-MeO-MiPT) is a 5-HT2A agonist which also blocks the 5-HT transporter (SERT) and has blunted visual and other psychedelic effects in humans. Here, we compared the pharmacology of 4-MeO-MiPT, its 4-hydroxy derivative (4-HO-MiPT), and related analogs with N-alkyl or 4-alkoxy variations. We hypothesized that compounds with more potent SERT uptake inhibition would display reduced 5-HT2A-mediated psychedelic-like effects in the mouse head twitch response (HTR) model. In vitro target profiling revealed potent and efficacious 5-HT receptor activities for most of the compounds, including 5-HT2A receptor agonism (EC50 = 10–118 nM, Emax = 72–97% 5-HT). Importantly, 4-MeO-MiPT and its N,N-diisopropyl (4-MeO-DiPT) and N-methyl-N-cyclopropyl (4-MeO-McPT) analogs displayed more potent uptake inhibition at SERT (IC50 = 17–107 nM) than their 4-OH counterparts (IC50 = 280–423 nM). Studies administering the drugs subcutaneously to C57BL/6J mice revealed that 4-HO- and 4-MeO-MiPT (0.03–30 mg/kg) had similar potencies for inducing HTRs (ED50 = 0.75 vs 0.97 mg/kg), but 4-MeO-MiPT had reduced efficacy (Emax = 77 vs 34 HTRs/30 min). A similar trend for decreased HTRs was observed for 4-MeO-DiPT and 4-MeO-McPT. Pretreatment with the SERT inhibitor fluoxetine (10 mg/kg) prior to 4-HO-MiPT, 4-HO-DiPT, or 4-HO-McPT reduced the maximal number of HTRs to levels observed for their respective 4-MeO analogs. Overall, our data indicate that 4-MeO-MiPT interacts with 5-HT2A and other 5-HT receptors, but the drug also inhibits SERT to reduce the efficacy of psychedelic-like effects in mice. Therefore, 4-MeO-MiPT and other dual 5-HT2A/SERT ligands may be therapeutically relevant compounds with reduced potential for traditional acute psychedelic effects.
期刊介绍:
ACS Chemical Neuroscience publishes high-quality research articles and reviews that showcase chemical, quantitative biological, biophysical and bioengineering approaches to the understanding of the nervous system and to the development of new treatments for neurological disorders. Research in the journal focuses on aspects of chemical neurobiology and bio-neurochemistry such as the following:
Neurotransmitters and receptors
Neuropharmaceuticals and therapeutics
Neural development—Plasticity, and degeneration
Chemical, physical, and computational methods in neuroscience
Neuronal diseases—basis, detection, and treatment
Mechanism of aging, learning, memory and behavior
Pain and sensory processing
Neurotoxins
Neuroscience-inspired bioengineering
Development of methods in chemical neurobiology
Neuroimaging agents and technologies
Animal models for central nervous system diseases
Behavioral research